is the fda stopping compounded tirzepatide says compounding pharmacies can keep making weight-loss med tirzepatide, for now FDA Announces End To Compounded

When compared with placebo or other therapies, GLP-1 agonists were associated with an increased risk of biliary disease [23]: Overall biliary disease: RR 1.37(95% CI 1.231.52) Cholelithiasis: RR 1.27 (95% CI 1.101.47) Cholecystitis: RR 1.36 (95% CI 1.141.62) Mechanisms: Reduced gallbladder motility Rapid weight loss increased cholesterol saturation and gallstone formation

Case reports of retained solid gastric content in patients undergoing anesthesia

Contraindications and precautions depend on the exact product

An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

They're most effective when combined with ongoing lifestyle changes, including healthy eating, regular physical activity, and adequate sleep

Footnotes 1